TITLE

Can acetylcysteine slow lung function decline in idiopathic pulmonary fibrosis?

AUTHOR(S)
Toma, T.
PUB. DATE
April 2006
SOURCE
Thorax;Apr2006, Vol. 61 Issue 4, p289
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
The article presents the abstract of the study "High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis," by M. Demedts, J. Behr and R. Buhl.
ACCESSION #
20604935

 

Related Articles

  • Fluoromicroscopic studies of bleomycin-induced intracellular oxidation in alveolar macrophages and its inhibition by taurine Rojanasakul, Yongyut; Bhat, Meenakshi; Ma, Jane Y. C.; Banks, Daniel E.; Castranova, Vincent; Weber, Susan L.; Ma, Joseph K. H. // Environmental Health Perspectives Supplements;1994 Supplement 10, Vol. 102, p91 

    No abstract available.

  • Diagnosis and management of idiopathic pulmonary fibrosis. Walling, Anne D. // American Family Physician;5/15/1998, Vol. 57 Issue 10, p2527 

    Presents information from the article `Cryptogenic Fibrosing Alveolitis,' by M. Chang-Yeung and N.L. Muller, which was published in the 1997 August issue of the `Lancet' journal. Prevalence of idiopathic pulmonary fibrosis in the United States; Therapy used to treat pulmonary fibrosis;...

  • On the Treatment for IPF.  // AARC Times;Jul2013, Vol. 37 Issue 7, p138 

    The article discusses a study conducted by researchers from the University of Alabama at Birmingham, about idiopathic pulmonary fibrosis.

  • Scientists Are Unraveling the Causes of Pulmonary Fibrosis.  // AARC Times;Mar2015, Vol. 39 Issue 3, p44 

    The article discusses a study which found that the fibrotic tissue which causes of pulmonary fibrosis could be the results of a direct damage of lung tissue due to too much fat and immune cells that initiate the scarring process.

  • First treatment approved for idiopathic pulmonary fibrosis.  // British Journal of Hospital Medicine (17508460);Apr2011, Vol. 72 Issue 4, p189 

    The article reports on the European Union's (EU's) approval of Esbriet (pirfenidone), the first treatment to be authorized by the body for adults with mild to moderate idiopathic pulmonary fibrosis.

  • Propylthiouracil.  // Reactions Weekly;4/9/2011, Issue 1346, p35 

    The article describes the case of a 62-year-old woman who acquired nonspecific interstitial pneumonia (NSIP) while undergoing treatment with propylthiouracil.

  • Antiinflammatory and Antifibrotic Properties of Colchicine: Implications for Idiopathic Pulmonary Fibrosis. Entzian, P.; Schlaak, M.; Seitzer, U.; Bufe, A.; Acil, Y.; Zabel, P. // Lung;1997, Vol. 175 Issue 1, p41 

    The ancient drug colchicine has repeatedly been proposed as a novel drug for therapy of pulmonary fibrosis. The present study was undertaken to add to the knowledge on colchicine's antiinflammatory and antifibrotic properties and thus help determine its actual rank in the treatment of...

  • Letters to the Editor. Vitums, V.C. // Archives of Environmental Health;Mar/Apr78, Vol. 33 Issue 2 

    Examines the mechanism of pulmonary fibrosis from amorphous silica dust. Details of the electron micrograph of silica dust taken from the plant of its origin; Production of granulomatous lesions with progressive collagenization of lungs by the silica; Component of crystalline silica.

  • Mineralogical Microanalysis of Idiopathic Pulmonary Fibrosis. Monso, Eduard; Tura, Josep Maria; Marsal, Montserrat; Morell, Ferran; Pujadas, Joan; Morera, Josep // Archives of Environmental Health;May/Jun90, Vol. 45 Issue 3 

    Examines the mineralogical microanalysis of idiopathic pulmonary fibrosis (IPF). Investigation of the tissue destruction of the lungs; Impact of silica on lungs; Distinction between the silica ratio in patients with IPF.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics